Propanc publishes recombinant proenzyme study in peer-reviewed journal

Propanc Biopharma, Inc. (NASDAQ: PPCB) announced that the company and research partners at the Universities of Jaén and Granada published findings in Microbial Cell Factories, a peer-reviewed journal focused on applied microbiology.

The publication, titled "Evaluation of recombinant trypsinogen and chymotrypsinogen production in Komagataella phaffii through co-expression of HAC1 and PDI1," examines the production of recombinant trypsinogen and chymotrypsinogen for potential use in biotechnology research and human therapeutic applications, including treatment of cancer and fibrosis.

Research conducted by Dr. Aitor González found that it is possible to scale up production of both proenzymes — trypsinogen and chymotrypsinogen — using recombinant technology, yielding stable purified proteins.

The resulting recombinant product candidate, designated rec-PRP, is intended as a follow-on to the company's lead asset, PRP, which is targeting a Phase 1b First-In-Human clinical study in advanced solid tumor cancer patients in early 2027. Rec-PRP will initially be produced at small scale under non-GMP conditions to establish compatibility with the naturally derived, bovine-sourced product before a regulatory pathway is determined.

According to the press release, the proenzymes can be synthesized to produce crystallized proteins that may remain stable for extended periods without refrigeration, a feature the company notes could aid global distribution.

"A fully synthetic recombinant version of PRP is the next phase of our strategic plan in building a new therapeutic drug class aimed at treating a range of chronic diseases," said James Nathanielsz, Propanc's Chief Executive Officer.

You May Also Be Interested In

• RBC Capital Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Sector Perform
• Jefferies Downgrades Xior Student Housing NV (XIOR:BB) to Hold
• Motilal Oswal Securities Starts V2 Retail Ltd (VREL:IN) at Buy